ClinicalTrials.gg
CompletedNCT04819464Updated Sep 22, 2025

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

A Phase 1 interventional study of Cenerimod in Healthy and Hepatic Impairment, sponsored by Viatris Innovation GmbH. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

This is a prospective, open-label, single-dose, phase 1 study, to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of cenerimod (ACT-334441).

02

Conditions studied

  • Healthy
  • Hepatic Impairment
03

In context

Lead sponsor

Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the participant prior to any study-mandated procedure.
  • Women of child bearing potential must have a negative serum pregnancy test at screening, a negative urine pregnancy test on Day -1, and must agree to consistently and correctly use a highly effective method of (i.e., failure rate of less than 1%).
  • Women of non- must have a medical history of previous bilateral salpingectomy, salpingo-oophorectomy or hysterectomy, premature ovarian failure confirmed by a specialist gynecologist; or, be , defined as 12 consecutive months with amenorrhea prior to screening without alternative medical cause and confirmed with a follicle-stimulating hormone test.
  • of 18.0 to 32.0 kg/m2 (inclusive) at screening.
  • Negative SARS-CoV-2-testing prior to Day -1 or documented vaccination against COVID-19 at least 3 months prior screening.
  • Ability to communicate well with the investigator, in a language understandable to the participant, and to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

General (Group A, B and C)

  • Pregnant or lactating women.
  • Participation in a clinical study involving study treatment administration within 30 days prior to screening or in more than 2 clinical studies within 1 year prior to screening.
  • Previous exposure to cenerimod.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, elimination (ADME) of the study treatment except for those related to liver cirrhosis or appendectomy and herniotomy.
  • greater than 2 at screening.
  • Encephalopathy grade greater than or equal to 1.
  • abnormalities on a 12-lead , recorded after 5 minutes in the supine position at screening and on Day 1 pre-dose.
  • Presence of herpes simplex, disseminated zoster, or other opportunistic infections.
  • Vaccination with live or in the previous 4 weeks.
  • Previous treatment with antiarrhythmic medications of class Ia or III 2 weeks or 5 half-lives, whichever is longer, prior to study treatment administration.
  • Active retinopathy or macular edema at screening.
  • Severe at screening.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • Legal incapacity or limited legal capacity at screening.

Additional exclusion criteria for participants with hepatic impairment (Group A and B)

  • Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at screening and on Day -1, except for those related to liver cirrhosis.

Additional exclusion criteria for healthy subjects (Group C)

  • Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at screening and on Day -1.
  • Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St. John\'s Wort, homeopathic preparations, vitamins, and minerals) within 2 weeks or 5 t½ prior to study treatment administration, whichever is longer (excluding and HRT).
  • and alanine aminotransferase above the .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group A: Participants with mild hepatic impairment

    Participants with mild hepatic impairment (Child-Pugh Score of 5 to 6).

    Drug: Cenerimod

  • Experimental
    Group B: Participants with moderate hepatic impairment

    Participants with moderate hepatic impairment (Child-Pugh Score of 7 to 9).

    Drug: Cenerimod

  • Experimental
    Group C:Healthy participants

    Healthy participants will be matched to the participants with hepatic impairment based on age and body weight.

    Drug: Cenerimod

Interventions

  • A single oral dose of 0.5 mg.

    Also known as: ACT-334441

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curves (AUC0-t): cenerimod

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.

  2. Area under the plasma concentration-time curve from zero to infinity (AUC0-inf): cenerimod

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.

  3. Maximum plasma concentration (Cmax): cenerimod.

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.

  4. Time to reach Cmax (tmax): cenerimod

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.

  5. Terminal half-life (t½): cenerimod

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.

  6. Plasma protein binding of cenerimod

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.

  7. Apparent clearance (CL/F) of cenerimod

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.

  8. Apparent volume of distribution (Vz/F) of cenerimod

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.

Secondary outcomes

  1. Total lymphocyte count

    Time frame: Multiple sampling at predefined times on Day 1 (pre-dose) up to Day 98.

  2. Change from baseline at each time point of measurement in electrocardiogram QT interval

    Time frame: Pre-defined times on Day 1 (pre-dose) up to Day 105.

  3. Change from baseline in body weight

    Time frame: Day -1 and Day 105.

  4. Change from baseline in systolic and diastolic blood pressure (in the supine position)

    Time frame: Predefined times on Day 1 (pre-dose) up to Day 105.

  5. Incidence of abnormal laboratory test results

    Time frame: Multiple sampling at predefined times on Day 1 (pre-dose) up to Day 105.

  6. Adverse events and serious adverse events

    Time frame: Day 1 up to Day 105.

07

Study locations

2 sites
  • CRU Hungary
    Kistarcsa, H2143, Hungary
  • BlueClinical Phase 1 Hospital de Prelado
    Porto, 4250-449, Portugal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Aug 2024, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2021
First posted
Mar 29, 2021
StartActual
Aug 25, 2021
Primary completionActual
Aug 18, 2024
CompletionActual
Aug 18, 2024
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04819464
Responsible party
Sponsor
First posted
Mar 29, 2021
Start date
Aug 25, 2021
Primary completion
Aug 18, 2024
Completion
Aug 18, 2024
Last update
Sep 22, 2025

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenerimod

Start the discussion